Kineta is a Seattle-based biotechnology company focused on developing next-generation immunotherapies and addressing mechanisms of cancer immune resistance.
The company's innovative approach includes the development of KVA12123, a VISTA blocking cancer therapy, with the aim of revolutionizing cancer treatment.
Generated from the website